ArticleThe EMBO journal2003
The C-terminal portion of RAG2 protects against transposition in vitro.
Article in The EMBO journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 70 citations in OpenAlex.
- Functional regulation of an ancestral RAG transposon ProtoRAG by a trans-acting factor YY1 in lancelet.Nature communications · 2020Article
- Co-evolution of mutagenic genome editors and vertebrate adaptive immunity.Current opinion in immunology · 2020Review
- Cut-and-Run: A Distinct Mechanism by which V(D)J Recombination Causes Genome Instability.Molecular cell · 2019Article
- The ESC: The Dangerous By-Product of V(D)J Recombination.Frontiers in immunology · 2019Review
- New insights into the evolutionary origins of the recombination-activating gene proteins and V(D)J recombination.The FEBS journal · 2017Review
- RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks.The Journal of experimental medicine · 2017Article
- Article
- V(D)J Recombination: Mechanism, Errors, and Fidelity.Microbiology spectrum · 2014Review
- Real-time monitoring of RAG-catalyzed DNA cleavage unveils dynamic changes in coding end association with the coding end complex.Nucleic acids research · 2012Article
- Mechanistic basis for RAG discrimination between recombination sites and the off-target sites of human lymphomas.Molecular and cellular biology · 2012Article
- Autoinhibition of DNA cleavage mediated by RAG1 and RAG2 is overcome by an epigenetic signal in V(D)J recombination.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- V(D)J recombination: Born to be wild.Seminars in cancer biology · 2010Review
- RAG: a recombinase diversified.Nature immunology · 2009Review
- Understanding how the V(D)J recombinase catalyzes transesterification: distinctions between DNA cleavage and transposition.Nucleic acids research · 2008Article
- Article
- Chromosomal reinsertion of broken RSS ends during T cell development.The Journal of experimental medicine · 2007Article
- In vivo reinsertion of excised episomes by the V(D)J recombinase: a potential threat to genomic stability.PLoS biology · 2007Article
- Requirements for DNA hairpin formation by RAG1/2.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Target DNA structure plays a critical role in RAG transposition.PLoS biology · 2006Article
- Mobilization of RAG-generated signal ends by transposition and insertion in vivo.Molecular and cellular biology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The assembly of antigen receptor genes by V(D)J recombination is initiated by the RAG1/RAG2 protein complex, which introduces double-strand breaks between recombination signal sequences and their coding DNA. Truncated forms of RAG1 and RAG2 are functional in vivo and have been used to study V(D)J cleavage, hybrid joint formation and transposition in vitro. Here we have characterized the activities of the full-length proteins. Unlike core RAG2, which supports robust transposition in vitro, full-length RAG2 blocks transposition of signal ends following V(D)J cleavage. Thus, one role of this non-catalytic domain may be to prevent transposition in developing lymphoid cells. Although full-length RAG1 and RAG2 proteins rarely form hybrid joints in vivo in the absence of non-homologous end-joining factors, we show that the full-length proteins alone can catalyze this reaction in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.